Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T15362 |
FX-11
LDHA Inhibitor FX11 |
Dehydrogenase | Metabolism |
FX-11 (LDHA Inhibitor FX11) 是一种有效的、选择性的和竞争性的乳酸脱氢酶 A (LDHA) 的特异性抑制剂,对LDHA 的Ki 为 8 μM。FX-11 对PKM2 (丙酮酸激酶 M2)具有激活作用。FX-11 可降低 ATP 水平,诱导氧化应激和ROS 生成,可引起细胞死亡。FX-11 在淋巴瘤和胰腺癌异种移植过程中表现出抗肿瘤 活性。 | |||
T3175 |
LDHA-IN-4
AZ 33,AZ-33,LDHA Inhibitor,AZ33 |
Dehydrogenase | Metabolism |
LDHA-IN-4 (AZ33) 是乳酸脱氢酶 A 选择性抑制剂,IC50=0.5 μM,Kd=0.093 μM。 | |||
T4295 |
(R)-GNE-140
GNE-140 |
Dehydrogenase | Metabolism |
(R)-GNE-140 (GNE-140) 是 LDHA 抑制剂,能够作用于 LDHA (IC50:3 nM) 和 LDHB (IC50:3 nM)。它的活性是 S 型异构体的 18 倍。 | |||
T19831 |
Sodium Oxamate
草氨酸钠,oxamate sodium,Oxamic acid sodium salt,Aminooxoacetic acid sodium salt,SO |
Apoptosis; Dehydrogenase; CDK | Apoptosis; Cell Cycle/Checkpoint; Metabolism |
Sodium Oxamate (Oxamic acid sodium salt) 是一种 LDH 抑制剂,对 LDHA 特异性抑制。Sodium Oxamate 具有抗肿瘤活性,可以诱导细胞周期阻滞、细胞凋亡。 | |||
T15435 |
GSK2837808A
|
Dehydrogenase | Metabolism |
GSK2837808A 是一种选择性的乳酸脱氢酶A 抑制剂,对 hLDHA (IC50:2.6 nM) 和 hLDHB (IC50:43 nM)。 | |||
T39805 |
LDHA-IN-3
PSTMB,1-(phenylseleno)-4-(trifluoromethyl) benzene |
Dehydrogenase | Metabolism |
LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) 是一种有效的非竞争性乳酸脱氢酶(LDHA) 抑制剂,IC50值为 145.2 nM。LDHA-IN-3 是一种硒苯化合物,可用于研究癌症。 | |||
T11829 |
LDH-IN-1
|
Dehydrogenase | Metabolism |
LDH-IN-1 是新型的基于吡唑的人乳酸脱氢酶抑制剂,对于 LDHA 和 LDHB 的 IC50 分别为32和27 nM。 | |||
T24530 |
NHI-2
NHI 2 |
||
NHI-2 is an inhibitor of LDHA that acts by reducing lactate production in HeLa cells. | |||
T27421 |
GNE-140 racemic
GNE-140,GNE 140,GNE140 |
||
GNE-140 racemic is a potent lactate dehydrogenase (LDHA) inhibitor. | |||
T73222 | LDHA-IN-5 | ||
LDHA-IN-5为新型且有效的GO/LDHA双重抑制剂,旨在治疗原发性高草酸尿。 | |||
T13450L |
GNE-140 racemate
GNE-140 (racemate) |
Others | Others |
GNE-140 is a potent inhibitor of lactate dehydrogenase A (LDHA). GNE-140 is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. | |||
T60995 |
LDHA/PDKs-IN-2
|
||
LDHA/PDKs-IN-2 (compound 20k) 是有效的 LDHA 和 PDKs 的双重抑制剂,IC50 值分别为 0.7 和 1.6 μM。LDHA/PDKs-IN-2 会增加耗氧量并且减少乳酸的形成。LDHA/PDKs-IN-2 显示了癌症研究的潜力,它可以减少 A549 细胞的增殖,EC50值为 15.7 μM。 | |||
T61339 | LDHA/PDKs-IN-1 | ||
LDHA/PDKs-IN-1 (compound 20e) is a highly effective dual inhibitor of PDKs and LDHA, displaying IC50 values of 0.8 μM and 0.15 μM, respectively. It significantly suppresses A549 cell proliferation (EC50 = 13.2 μM), reduces lactate formation, and enhances oxygen consumption. This compound holds great promise for cancer research [1]. | |||
T79204 |
Anticancer agent 122
|
||
Anticanceragent 122,作为一种hLDHA抑制剂,表现出显著的抗癌活性,主要应用于抗肿瘤研究。 | |||
T79874 |
CHK-336
|
||
CHK-336(Example 1)为口服活性LDHA抑制剂(IC50<1 nM),有效抑制小鼠肝细胞产生乳酸。该化合物适用于高草酸尿症相关研究。 |